vidarabine has been researched along with Leukemia, Myeloid, Acute in 421 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (1.19) | 18.7374 |
| 1990's | 28 (6.65) | 18.2507 |
| 2000's | 91 (21.62) | 29.6817 |
| 2010's | 221 (52.49) | 24.3611 |
| 2020's | 76 (18.05) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J; Atsuta, Y; Fukuda, T; Imada, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y | 1 |
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Fleischmann, M; Frietsch, JJ; Glaser, A; Hammersen, J; Hilgendorf, I; Hochhaus, A; Mühleck, R; Sayer, HG; Schnetzke, U; Scholl, S; Schrenk, K | 1 |
| Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Appelbaum, FR; Cooper, JP; Deeg, HJ; Doney, K; Flowers, MED; Gooley, T; Martin, PJ; McCune, JS; McFarland, C; O'Donnell, PV; Schoch, G; Sorror, ML; Storer, BE; Yeh, AC | 1 |
| Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB | 1 |
| Burnett, A; Dennis, M; Hills, R; Kjeldsen, L; Russell, N | 1 |
| Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A | 1 |
| Admiraal, R; Bierings, M; Blok, H; Calkoen, FG; De Koning, C; Dekker, L; Hoogerbrugge, P; Huitema, ADR; Jiang, Y; Lindemans, CA; Nierkens, S; Nijstad, AL; Pieters, R; Spoon, M; Van Der Elst, KCM; Van Der Vlugt, M; Van Tinteren, H; Veldkamp, SR; Visscher, H; Vormoor, B; Vormoor, HJ | 1 |
| Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B | 1 |
| Atsuta, Y; Fukuda, T; Imada, K; Ishiyama, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kimura, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y | 1 |
| Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M | 1 |
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Bazarbachi, A; Bethge, W; Blau, IW; Bondarenko, S; Brecht, A; Brissot, E; Bulabois, CE; Eder, M; Einsele, H; Forcade, E; Giebel, S; Huynh, A; Labopin, M; Mohty, M; Nagler, A; Rodríguez-Arbolí, E; Savani, B; Schmid, C; Spyridonidis, A; Stölzel, F; Tischer, J; Verbeek, M | 1 |
| Azarnoush, S; Dhunputh, C; Ducassou, S; Leverger, G; Merched, M; Pasquet, M; Petit, A; Strullu, M | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M | 1 |
| Burns, LJ; Nathan, S; Ustun, C; Warlick, E; Weisdorf, D | 1 |
| Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC | 1 |
| Basara, N; Baumgart, J; Beelen, DW; Benedetti, F; Bethge, W; Bieniaszewska, M; Casper, J; Ciceri, F; Dreger, P; Finke, J; Glass, B; Grigoleit, GU; Hilgendorf, I; Holler, E; Junghanß, C; Klein, A; La Rocca, U; Labussiere-Wallet, H; Markiewicz, M; Niederwieser, D; Patriarca, F; Pichlmeier, U; Rambaldi, A; Reményi, P; Russo, D; Schaefer-Eckart, K; Scheid, C; Socié, G; Stelljes, M; Stölzel, F; Stuhler, G; Verbeek, M; Wagner-Drouet, EM; Wulf, G | 1 |
| Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Bhojwani, D; Burke, MJ; Chao, K; Colace, SI; Doan, A; Gossai, NP; Guinipero, T; Hilsenbeck, SG; Hinson, A; Jo, E; Kaplan, JA; Otterson, D; Pommert, L; Schafer, ES; Stevens, AM; Wayne, AS | 1 |
| Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM | 1 |
| Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X | 1 |
| Cioccio, J; Claxton, DF; Ehmann, WC; Minagawa, K; Mineishi, S; Naik, S; Nickolich, M; Pizzola, CJ; Rakszawski, KL; Rybka, WB; Shike, H; Silar, B; Wirk, B; Zheng, H; Zhou, S | 1 |
| Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z | 1 |
| Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I | 1 |
| Arat, M; Berceanu, A; Giebel, S; Hamladji, RM; Kröger, N; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Potter, V; Rambaldi, A; Sanz, J; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R; Yakoub-Agha, I | 1 |
| Abuasab, T; Alvarado, Y; Borthakur, G; Brandt, MA; Daver, N; DiNardo, C; Haddad, FG; Kadia, T; Kantarjian, H; Pemmaraju, N; Ravandi, F; Senapati, J | 1 |
| Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M | 1 |
| Albano, F; Attolico, I; Carluccio, P; Contento, C; Delia, M; Di Gennaro, D; Gagliardi, VP; Musto, P | 1 |
| Bhojwani, D; Dao, J; Doan, A; Freyer, DR; Gaynon, P; Hadar, AJ; Huang, HKT; Kovach, AE; Malvar, J; Orgel, E; Parekh, C; Posch, LC; Raca, G; Rushing, T; Stokke, J | 1 |
| Fan, Z; Guo, Z; Huang, F; Jin, H; Liang, X; Lin, R; Ling, Y; Liu, C; Liu, H; Liu, Q; Liu, X; Ou, R; Qu, H; Sun, J; Wu, M; Xu, N; Xu, X; Xuan, L; Yu, S; Zhai, X; Zhang, H; Zhang, Y; Zhao, Y | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
| Agarwal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mirgh, SP; Shaikh, MR; Singh, B; Singh, R | 1 |
| Booth, C; Kohn, DB; Long-Boyle, JR; López Lorenzo, JL; Matos, J; Nicoletti, E; Reatz, M; Schwartz, JD; Sevilla, J; Shah, A; Shah, AJ; Spencer, SM | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Al-Atrash, G; Alousi, A; Bashir, Q; Betul, O; Bittencourt, MCB; Champlin, RE; Ciurea, SO; Daver, N; Hosing, C; Jabbour, E; Kantarjian, H; Kebriaei, P; Khouri, I; Kongtim, P; Konopleva, M; Masarova, L; Mehta, R; Olson, A; Perez, JMR; Popat, U; Ravandi, F; Saliba, RM; Short, N; Srour, SA | 1 |
| Shimoni, A | 1 |
| Bolwell, B; Gerds, AT; Hamilton, BK; Hanna, R; Kalaycio, M; Majhail, NS; Patel, SS; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Blaise, D; Choi, G; Cornelissen, J; Heinicke, T; Kuball, J; Labopin, M; Mohty, M; Nagler, A; Niederwieser, D; Paul, F; Platzbecker, U; Polge, E; Potter, V; Savani, BN; Schaap, N; Sengelov, H; van Gorkom, G | 1 |
| Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J | 1 |
| Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R | 1 |
| Alousi, A; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Daver, N; Hosing, C; Kongtim, P; Konopleva, M; Mehta, R; Olson, A; Oran, B; Popat, U; Rondon, G; Srour, S; Varma, A | 1 |
| Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E | 1 |
| Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A | 1 |
| Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, MM; Solomon, SR; Zhang, X | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S | 1 |
| Akasaka, T; Atsuta, Y; Eto, T; Fukuda, T; Hidaka, M; Kanda, J; Kondo, T; Miyakoshi, S; Ota, S; Shiratori, S; Takami, A; Uchida, N; Yamashita, T; Yano, S | 1 |
| Byrd, JC; Lee, DA; Mani, R; Mo, X; Muthusamy, N; Nunes, J; Rajgolikar, G; Vasu, S; Wasmuth, R; Zapolnik, K | 1 |
| Bertrand, Y; Girard, S; Marceau-Renaut, A; Penel-Page, M; Plesa, A; Renard, C | 1 |
| Baron, F; Hsu, J; Van Besien, K | 1 |
| Akashi, K; Eto, T; Fujishima, N; Harada, M; Hidaka, M; Kishimoto, J; Maeda, Y; Matsumoto, K; Miyamoto, T; Mori, SI; Morita, K; Murayama, T; Sakura, T; Taniguchi, S; Teshima, T; Uchida, N; Yamashita, T; Yoshimoto, G | 1 |
| Callander, N; D'Angelo, CR; Hall, A; Hematti, P; Juckett, M; Kenkre, VP; Kim, K; Longo, W; Mattison, R; Woo, KM | 1 |
| Beelen, DW; Blaise, D; Bornhäuser, M; Byrne, JL; Fegueux, N; Giebel, S; Karadogan, I; Labopin, M; Mohty, M; Nagler, A; Rovira, M; Savani, BN; Sobczyk-Kruszelnicka, M; Spyridonidis, A; Stelljes, M | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y | 1 |
| Chu, X; Fang, X; Geng, L; Liu, H; Qiang, P; Song, K; Sun, G; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, X; Zhu, X | 1 |
| Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I | 1 |
| Arabi, A; Bazarbachi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Serradj, F; Yafour, N | 1 |
| Brammer, JE; Choe, H; Dickerson, T; Elder, P; Jaglowski, S; Larkin, K; Mims, A; Penza, S; Puto, M; Rasor, B; Roddy, JVF; Saad, A; Vasu, S; Wall, SA; William, B; Zhao, Q | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Abrahamsson, J; Boelens, JJ; Bordon, V; Buechner, J; Ifversen, M; Jackmann, N; Lankester, A; Mellgren, K; Pronk, C; Sundin, M; Versluys, AB; Vettenranta, K | 1 |
| Ayash, L; Deol, A; Kim, S; Modi, D; Ratanatharathorn, V; Singh, V; Uberti, JP | 1 |
| Chamo, M; Gazit, R; Goldstein, O; Ilic, S; Keinan, N; Scharff, Y | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| Benitez, LL; Bixby, DL; Boyer, D; Burke, PW; Lee, W; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Abedi, M; Hoeg, RT; Jonas, BA; Krishnan, R; Moskoff, BN; Rosenberg, AS; Tenold, ME; Tuscano, JM | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Cho, HW; Hyun, JK; Ju, HY; Koo, HH; Lee, JW; Lim, DH; Sung, KW; Yoo, KH | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| Atsuta, Y; Eto, T; Fukuda, T; Hara, M; Hirabayashi, S; Ichinohe, T; Kanda, Y; Kawakita, T; Kimura, T; Kondo, T; Maruyama, Y; Mizuno, S; Mukae, J; Nakano, N; Ota, S; Ozawa, Y; Shimomura, Y; Tanaka, M; Uchida, N; Yanada, M | 1 |
| Davainis, L; Griskevicius, L; Maneikis, K; Peceliunas, V; Pileckyte, R; Staras, V; Trociukas, I; Vaitekenaite, V; Zucenka, A; Zvirblis, T | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J | 1 |
| Afanasyev, B; Bethge, W; Brand, R; de Witte, T; Deliliers, GL; Dreger, P; Franke, GN; Guidi, S; Günther, A; Heim, D; Hübel, K; Iacobelli, S; Kobbe, G; Kröger, N; Onida, F; Pini, M; Platzbecker, U; Poiré, X; Robin, M; Scheid, C; Stelljes, M; Uddin, R; van Os, M; Volin, L; Weber, T | 1 |
| Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F | 1 |
| Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R | 1 |
| Buxhofer-Ausch, V; Geissler, K; Girschikofsky, M; Gleixner, K; Herndlhofer, S; Hoermann, G; Jaeger, U; Knoebl, P; Kundi, M; Machherndl-Spandl, S; Poehnl, R; Sliwa, T; Sperr, WR; Strecker, K; Valent, P; Weltermann, A | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Barker, JN; Boulad, F; Castro-Malaspina, H; Fuller, K; Hilden, PD; Hsu, KC; Jakubowski, AA; Kernan, NA; Koehne, G; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Scaradavou, A; Spitzer, B; van den Brink, MR; Young, JW | 1 |
| Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK | 1 |
| Albano, F; Carluccio, P; Casieri, P; Delia, M; Mestice, A; Pasciolla, C; Pastore, D; Ricco, A; Rossi, AR; Specchia, G | 1 |
| Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S | 1 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Altuntaş, F; Ayyildiz, MO; Bekdemir, F; Çakar, MK; Dal, MS; Dogu, MH; Hacioglu, SK; Ilkkiliç, K; Karakus, A; Kaya, AH; Korkmaz, S; Merdin, A; Tekgündüz, E | 1 |
| Bentz, M; Binnenhei, M; Bohl, SR; Bullinger, L; Bunjes, D; Döhner, H; Döhner, K; Drognitz, K; Kuchenbauer, F; Kündgen, L; Moulin, JC; Nguyen, TM; Ringhoffer, M; Schlenk, RF; Teleanu, V; von Harsdorf, S; Wais, V | 1 |
| Bixby, DL; Crouch, A; Marini, BL; Nachar, VR; Perissinotti, AJ; Scappaticci, GB; Talpaz, M; Uebel, JR; Vulaj, V | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G | 1 |
| Asma, S; Aytan, P; Boga, C; Gereklioglu, C; Kozanoglu, I; Maytalman, E; Ozdogu, H; Sariturk, C; Yeral, M | 1 |
| Barghout, SH; Chan, SM; Claudio, J; Gronda, M; Gupta, V; Heath, E; Hurren, R; Kamel-Reid, S; Kavanagh, S; Khalaf, D; Liyanage, SU; Lutynski, A; Maze, D; Minden, MD; Rostom, A; Rydlewski, A; Schimmer, AD; Schuh, AC; Sibai, H; Siriwardena, TP; Stockley, TL; Sukhai, M; Yee, K; Zhang, T | 1 |
| Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H | 1 |
| Amrolia, P; Breslin, P; Cummins, M; De La Fuente, J; Gassas, A; Gibson, B; Hiwarkar, P; Hough, R; James, B; Lawson, S; Patrick, K; Petterson, T; Potter, M; Shenton, G; Sivaprakasam, P; Skinner, R; Slatter, M; Veys, P; Vora, A; Wynn, R | 1 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ | 1 |
| Becktell, K; Burke, MJ; Houser, K | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Fang, X; Jiang, Y; Li, Y; Liu, X; Sui, X; Wang, X; Xu, H; Zhang, L | 1 |
| Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
| Blaise, D; Brecht, A; Cahn, JY; Heinicke, T; Hicheri, Y; Huynh, A; Labopin, M; Ledoux, MP; Milpied, N; Mohty, M; Mufti, GJ; Nagler, A; Polge, E; Savani, BN; Scheid, C; Schmid, C; Socié, G | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I | 1 |
| Blaise, D; Decroocq, J; Devillier, R; Fan, X; Fürst, S; Hu, J; Tian, L; Vey, N; Wan, M; Wang, L; Wang, LN | 1 |
| Bittenbring, J; Brecht, A; Canaani, J; Ganser, A; Labopin, M; Labussière-Wallet, H; Mayer, J; Mohty, M; Nagler, A; Savani, B; Sheth, V; Shouval, R; Volin, L | 1 |
| Baker, L; Holder, K; Kanellopoulos, A; Kaparou, M; Kishore, B; Lovell, R; Nikolousis, E; Paneesha, S; Ryan, L; Suhr, J; Xenou, E | 1 |
| Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V | 1 |
| Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J | 1 |
| Medeiros, BC | 2 |
| Inoue, A; Mori, A; Suzuki, R; Takitani, K; Tamai, H; Yamazaki, S | 1 |
| Dührsen, U; Hanoun, M; Noppeney, R; Westhus, J | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Bae, S; Costa, LJ; Erba, HP; Jamy, O; Papadantonakis, N | 1 |
| Hale, G; Kussman, A; Oshrine, B; Petrovic, A; Shyr, D | 1 |
| Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H | 1 |
| Luo, W; Ni, X; Wei, J; Yu, H; Zou, X | 1 |
| Levin-Epstein, R; Oliai, C; Schiller, G | 1 |
| Abdalla, K; Abrar, MB; AlAzmi, AA; Elimam, N; Jastaniah, W; Mustafa, O | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Li, LJ; Yu, K; Zhang, JY | 1 |
| Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Molldrem, JJ; Nieto, Y; Olson, A; Oran, B; Popat, UR; Qazilbash, MH; Rezvani, K; Shpall, EJ; Srour, SA | 1 |
| Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J | 1 |
| Baggerly, KA; Benton, CB; Champlin, R; Chen, J; Konoplev, S; Konopleva, M; Liu, W; Lu, H; Shpall, E; Wang, RY; Zeng, Z | 1 |
| Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME | 1 |
| Imanaga, H; Ohno, Y; Ohta, T; Oku, S; Sugio, Y | 1 |
| Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM | 1 |
| Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G | 1 |
| Brychtova, Y; Doubek, M; Dusek, J; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Compain, L | 1 |
| Kalaycio, M; Lukenbill, J | 1 |
| Chen, K; Darcy, PK; Dickinson, M; Gambell, P; Haurat, J; Hönemann, D; Kershaw, MH; Khot, A; Kravets, L; Neeson, PJ; Peinert, S; Prince, HM; Ritchie, DS; Scott, AM; Shin, M; Smyth, MJ; Tai, T; Tainton, K; Trapani, JA; Wall, DM; Westerman, DA; Westwood, JA | 1 |
| Burnett, AK; Gibson, BE; Hills, RK; Hunter, AE; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A | 1 |
| Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC | 1 |
| Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B | 1 |
| Aldoss, I; Haider, M; Ji, L; Pullarkat, V | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Ball, LM; Bredius, RG; Hissink Muller, P; Jol-van der Zijde, EC; Lankester, AC; Vermont, CL; Vossen, AC | 1 |
| Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B | 1 |
| Bae, SH; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Bekele, N; Borthakur, G; Estey, E; Jabbour, EJ; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, WK; Ravandi-Kashani, F; Tsimberidou, AM | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Estey, EE; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Koller, C; Luthra, R; O'Brien, S; Patel, K; Ravandi, F; Wang, X | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Alati, C; Console, G; Cuzzola, M; Dattola, A; Fedele, R; Gallo, GA; Irrera, G; Martinello, T; Martino, M; Messina, G; Molica, S; Moscato, T; Pontari, A; Princi, D; Ronco, F | 1 |
| Cao, X; Dong, W; Ling, Y; Liu, D; Wang, B; Yang, B | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lerner, S; O'Brien, S; Qiao, W; Strom, SS; Trinh, L; Wang, X; Wierda, W | 1 |
| Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y | 1 |
| Cox, EA; Cripe, LD; Farag, SS; Khawaja, MR; Kiel, PJ; Nelson, RP; Perkins, SM; Robertson, MJ; Sayar, H; Schwartz, JE; Vance, GH | 1 |
| Afanasyev, B; Baron, F; Deconinck, E; Jindra, P; Labopin, M; Mohty, M; Nagler, A; Peniket, A; Sanz, MA | 1 |
| Creutzig, U; Kaspers, GL; Reinhardt, D; Semmler, J; Zimmermann, M | 1 |
| Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bay, JO; Bilger, K; Bulabois, CE; Buzyn, A; Ceballos, P; Chevallier, P; Chevret, S; Clement, L; Cornillon, J; Dauriac, C; Françoise, S; Fürst, S; Gluckman, E; Huynh, A; Legrand, F; Maillard, N; Margueritte, G; Maury, S; Michallet, M; Michel, G; Milpied, N; Nguyen, S; Rio, B; Rocha, V; Ruggeri, A; Simon, T; Sirvent, A; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I | 1 |
| Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S | 1 |
| Adachi, S; Atsuta, Y; Goto, H; Hasegawa, D; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kawa, K; Koh, K; Kudo, K; Okamoto, Y; Yabe, H | 1 |
| Arthur, C; Fay, K; Gifford, G; Greenwood, M; Kerridge, I; Stevenson, W; Wong, K | 1 |
| Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC | 1 |
| Bixby, D; Braun, T; Choi, S; Churay, T; Couriel, DR; Frame, D; Goldstein, SC; Harris, A; Kitko, C; Levine, J; Li, Y; Magenau, JM; Mineishi, S; Parkin, B; Pawarode, A; Reddy, P; Riwes, MM; Yanik, G | 1 |
| Alousi, A; Anderlini, P; Andreeff, M; Benton, CB; Champlin, R; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Kebriaei, P; Konopleva, M; Lu, H; McMullin, B; Nieto, Y; Parmar, S; Popat, U; Qiao, W; Rondon, G; Schober, W; Shpall, E; Thall, PF; Wang, RY; Woodworth, G; Zeng, Z | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M | 1 |
| Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G | 1 |
| Bazarbachi, A; Beelen, D; Bermudez, A; Blaise, D; Fegueux, N; Hamladji, RM; Kharfan-Dabaja, MA; Kroeger, N; Labopin, M; Lioure, B; Mohty, M; Nagler, A; Or, R; Socie, G; Veelken, H | 1 |
| Asma, S; Boga, C; Kasar, M; Kozanoglu, I; Maytalman, E; Ozdogu, H; Yeral, M | 1 |
| Boga, C; Kasar, M; Kozanoglu, I; Ozdogu, H; Sariturk, C; Yeral, M | 1 |
| Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J | 1 |
| Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K | 1 |
| Alatrash, G; Andersson, BS; Champlin, R; Charafeddine, Y; Chen, J; Ciurea, S; Kebriaei, P; Lee, HC; Medeiros, LJ; Oran, B; Popat, U; Rondon, G; Saliba, RM; Shpall, E | 1 |
| Bethge, WA; Buechele, C; Faul, C; Federmann, B; Helwig, A; Kanz, L; Schmohl, J; Schneidawind, D; Vogel, W | 1 |
| Al-Ali, HK; Behre, G; Franke, GN; Hochhaus, A; Jentzsch, M; Klink, A; Niederwieser, D; Pfrepper, C; Sayer, HG; Schenk, T; Schwind, S | 1 |
| Alessandrino, EP; Arcese, W; Bacigalupo, A; Boschini, C; Bosi, A; Bruno, B; Busca, A; Carella, AM; Cavattoni, I; Chiusolo, P; Corradini, P; Grassi, A; Guidi, S; Marfisi, RM; Marotta, G; Masciulli, A; Micò, MC; Milone, G; Montanari, M; Mordini, N; Nagler, A; Oldani, E; Pastore, D; Patriarca, F; Pini, M; Raimondi, R; Rambaldi, A; Risitano, AM; Russo, D; Santarone, S; Saporiti, G; Scimè, R; Terruzzi, E; Torelli, GF | 1 |
| Alyea, EP; Blum, W; Carter, S; Champlin, RE; Chen, YB; Devine, SM; Giralt, S; Hars, V; Horowitz, MM; Hsu, JW; Larson, RA; Linker, C; Mulkey, F; Owzar, K; Shea, TC; Sibley, AB; Slack, J; Soiffer, RJ; Stone, RM; Vij, R | 1 |
| Giralt, S | 1 |
| Hubáček, J; Indrák, K; Jarošová, M; Marschalek, R; Meyer, C; Szotkowski, T; Zimmermannová, O; Zuna, J | 1 |
| Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K | 1 |
| Biemond, BJ; Cornelissen, JJ; Graux, C; Hazenberg, CL; Kuball, J; Löwenberg, B; Maertens, J; Ossenkoppele, G; Pabst, T; Passweg, JR; Schouten, HC; Theobald, M; van Putten, WL; Vellenga, E; Versluis, J | 1 |
| Andersson, BS | 1 |
| Boschini, C; Masciulli, A; Rambaldi, A | 1 |
| Bazarbachi, A; Kharfan-Dabaja, MA; Nishihori, T | 1 |
| Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Cooney-Qualter, E; Fabricatore, S; Harrison, L; Kletzel, M; Luisi, P; Militano, O; Morris, E; Ricci, A; Roy, S; van de Ven, C; Wolownik, K; Zahler, S | 1 |
| Chen, J; Hu, J; Huang, H; Huang, X; Jin, J; Li, J; Li, Y; Liang, Y; Ma, J; Sun, Y; Wang, C; Wang, J; Wang, L; Wu, D; Xiao, Y; Yu, K | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ | 1 |
| Ding, J; Jing, Y; Wang, HX; Wang, LJ; Yang, H; Yu, L; Zhu, CY | 1 |
| Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C | 1 |
| Çelik, Y; Maden, M; Pamuk, G; Ünlü, E | 1 |
| Bolster, L; Brandwein, J; Ghosh, S; Hamilton, M; Larratt, L; Liew, E; Mant, M; Patterson, JM; Peters, A; Ritchie, B; Saini, L; Sandhu, I; Turner, R; Wu, C; Zhu, N | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M | 1 |
| Amador-Barciela, ML; Barrios, M; Benavente, C; Bergua, JM; Fernández-Abellán, P; García, R; García-Huerta, AJ; Herrera-Puente, P; Martinez-Cuadrón, D; Martínez-Sánchez, MP; Montesinos, P; Pérez-Encinas, M; Prieto-Fernandez, J; Riaza-Grau, R; Rodríguez-Macias, G; Rodríguez-Veiga, R; Sanz, MA; Sayas, MJ; Serrano, J; Simiele, A | 1 |
| Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC | 1 |
| Akiyama, K; Aoki, T; Arakawa, Y; Hanada, R; Ikeda, Y; Koh, K; Mori, M; Sekinaka, Y | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Cheng, H; Hu, X; Li, R; Lv, S; Song, X; Wang, J; Wang, L; Yang, J; Zhang, W | 1 |
| Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Bonfigli, S; Careddu, MG; Coppola, L; Dessì, L; Dore, F; Dore, S; Fozza, C; Giannico, DB; Longinotti, M; Longu, F; Nieddu, RM; Pardini, S; Podda, L; Sotgiu, G | 1 |
| Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J | 1 |
| Damiani, D; Geromin, A; Tiribelli, M | 1 |
| Abounader, DM; Andresen, S; Bolwell, BJ; Dean, R; Ferraro, C; Gerds, AT; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Liu, H; Majhail, NS; Mustafa Ali, M; Pohlman, B; Rybicki, LA; Sobecks, RM; Starn, J; Winslow, V; Yurch, MA | 1 |
| Blaise, D; D'Aveni-Piney, M; Daguindeau, E; Diez-Martin, JL; Hamladji, RM; Irrera, G; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Richard, C; Rubio, MT; Santarone, S; Sanz, MA; Savani, BN; Yakoub-Agha, I; Yeshurun, M | 1 |
| Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P | 1 |
| Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Hayashi, Y; Horibe, K; Iwamoto, S; Miyamura, T; Mizutani, S; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E | 1 |
| Baccarani, M; Bergonzi, C; Bocchia, M; Bonini, A; Candoni, A; Damiani, D; De Rosa, F; Fanin, R; Filì, C; Gobbi, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Paolini, S; Peli, A; Piccaluga, PP; Pierri, I; Priccolo, G; Roccaro, AM; Russo, D; Skert, C; Tiribelli, M; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
| Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR | 1 |
| Borthakur, G; Estey, EH; Faderl, S; Gandhi, VV; Garcia-Manero, G; Kantarjian, H; Pierce, S; Plunkett, WK; Ravandi, F; Wang, X | 1 |
| Champlin, RE; Couriel, D; de Lima, M; de Souza, J; Giralt, S; Komanduri, KV; Oran, B; Patah, P; Rondon, G; Saliba, RM | 1 |
| Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Chen, ZC; Li, QB; Li, WM; Xia, LH; You, Y; Zhou, H; Zou, P | 1 |
| Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A | 1 |
| Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF | 1 |
| Andersson, BS; Champlin, RE; de Lima, M; Madden, T; Russell, JA; Thall, PF | 1 |
| Champlin, RE; de Lima, M; de Padua Silva, L; de Souza, JA; Efebera, Y; Hosing, C; Patah, P; Popat, U; Qazilbash, MH; Ribeiro, R; Rondon, G; Saliba, RM | 1 |
| Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Hong, M; Li, JY; Li, Q; Lu, H; Qian, SX; Qiu, HX; Sheng, WY; Wu, HX; Xu, W; Zhang, R | 1 |
| Gharabaghi, F; Leahy, TR; Punnett, AS; Richardson, SE; Wadhwa, A | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W | 1 |
| Abonour, R; Baute, JA; Cornetta, K; Cox, EA; Cripe, LD; Dlouhy, SR; Farag, SS; Fausel, CA; Haut, PR; Hromas, R; Nelson, RP; Robertson, KA; Robertson, MJ; Schwartz, JE; Srivastava, S; Vance, GH; Wood, LL; Yu, M | 1 |
| Bell, T; Inaba, H; Leung, W; Pounds, S; Pui, CH; Ribeiro, RC; Rooney, B; Rubnitz, JE | 1 |
| Abad, L; Diaz, MA; Gonzalez-Vicent, M; Perez, A; Ramirez, M; Sevilla, J | 1 |
| Appelbaum, FR; Douglas, JG; Mayadev, JS; Storb, R; Storer, BE | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW | 1 |
| Jabbour, E; Kadia, T; Parikh, SA | 1 |
| Anasetti, C; Ayala, E; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kim, J; Perez, L; Perkins, J; Pidala, J | 1 |
| Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Angchaisuksiri, P; Apilugsanachit, A; Atichartakarn, V; Boonsakan, P; Chuncharunee, S; Jootar, S; Kanoksil, W; Karntisaviwat, K; Niparuck, P; Nitiyanant, P; Rerkamnuatchoke, B; Ungkanont, A | 1 |
| Carney, DA; Seymour, JF | 1 |
| Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC | 1 |
| Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
| Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL | 1 |
| Came, N; Carney, DA; Januszewicz, EH; Kenealy, M; Milner, A; Prince, HM; Ritchie, D; Seymour, JF; Tam, CS; Westerman, DA; Wolf, M | 1 |
| Anderlini, P; Andersson, BS; Bashir, Q; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Fernandez-Vina, M; Giralt, S; Popat, U; Rodrigues, M; Sharma, M; Shpall, EJ; Wei, W | 1 |
| Choi, MK; Chung, CW; Hong, JY; Jang, JH; Kim, DH; Kim, HO; Kim, K; Kim, SJ; Kim, WS; Min, YH | 1 |
| Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
| Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C | 1 |
| Brunstein, CG; DeFor, TE; Oran, B; Wagner, JE; Weisdorf, DJ | 1 |
| de Lima, M; de Souza Santos, FP; Hamerschlak, N; Kerbauy, FR; Kutner, JM; Ribeiro, AA; Rodrigues, M; Sobrinho, JN; Torres, MA | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Byrd, JC; Gribben, JG; Heerema, NA; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Ruppert, AS; Woyach, JA | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W | 1 |
| Baurmann, H; Braess, J; Buechner, T; Haferlach, C; Hahn, J; Haude, KH; Hiddemann, W; Holler, E; Kolb, HJ; Oruzio, D; Schleuning, M; Schlimok, G; Schmid, C; Schwerdtfeger, R; Spiekermann, K; Tischer, J | 1 |
| Alousi, AM; Anderlini, P; Andersson, BS; Champlin, RE; de Lima, MJ; Giralt, SA; Hosing, C; Kebriaei, P; Khouri, IF; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Saliba, RM | 1 |
| Shen, ZX | 1 |
| Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M | 1 |
| Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M | 1 |
| Bae, SH; Choi, SJ; Hyun, MS; Jeon, M; Joo, YD; Kang, MJ; Kang, YA; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Lee, YS; Park, JH; Ryoo, HM; Seol, M; Yun, SC | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J | 1 |
| Burchert, A; Neubauer, A; Wilhelm, C | 1 |
| Solis, EC | 1 |
| Colović, M; Colović, N; Fekete, MD; Janković, G; Palibrk, V; Suvajdžić, N; Tomin, D | 1 |
| Baccarani, M; Bandini, G; Bontadini, A; Curti, A; D'Addio, A; Dan, E; Fruet, F; Giudice, V; Isidori, A; Lemoli, RM; Martinelli, G; Motta, MR; Paolini, S; Parisi, S; Ruggeri, L; Trabanelli, S; Urbani, E; Velardi, A | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ | 1 |
| Baumgart, J; Beelen, DW; Blau, I; Bornhaeuser, M; Casper, J; Einsele, H; Freund, M; Giebel, S; Holowiecki, J; Kruzel, T; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Ruutu, T; Schaefer-Eckart, K; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Wandt, H; Zander, AR | 1 |
| Borthakur, G; Cortes, J; Eghtedar, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El Cheikh, J; Esterni, B; Etienne, A; Faucher, C; Fürst, S; Prebet, T; Vey, N | 1 |
| Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R | 1 |
| Faber, E; Hubacek, J; Indrak, K; Jarosova, M; Katrincsakova, B; Kurfurst, P; Pikalova, Z; Raida, L; Rusinakova, Z; Skoumalova, I; Tucek, P; Vondrakova, J | 1 |
| Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E | 1 |
| Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R | 1 |
| Aisa, Y; Kato, J; Mori, T; Nakamura, Y; Nakazato, T; Okamoto, S; Shigematsu, N | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E | 1 |
| Cao, XS; Wang, B; Yang, B | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B | 1 |
| Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| Canaani, J; Dezorella, N; Eshel, R; Gepstein, L; Herishanu, Y; Naparstek, E; Perry, C; Polliack, A; Rothman, R; Sarid, N; Shpringer, M; Solar, I | 1 |
| Bo, L; Chen, F; Fang, Y; Fu, J; Li, Y; Liang, A; Lu, H; Zhang, H; Zhu, D | 1 |
| Guo, M; Hu, KX; Qiao, JH; Sun, QY; Wang, YR; Yu, CL | 1 |
| Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Blaise, D; Siddiqi, T | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Liu, H; Liu, QF; Sun, J; Wu, MQ; Yu, GP; Zhang, X; Zhou, HS | 1 |
| Aleinikova, O; Armendariz, H; Bertrand, Y; Creutzig, U; Dworzak, M; Gibson, BE; Ha, SY; Hasle, H; Hovi, L; Kaspers, GJ; Leverger, GG; Maschan, A; Razzouk, BI; Reinhardt, D; Rizzari, C; Smisek, P; Smith, O; Stark, B; Tamminga, RY; Zimmermann, M | 1 |
| Bertz, H; Christopoulos, P; Finke, J; Marks, R; Schmoor, C; Wäsch, R; Waterhouse, M | 1 |
| Fan, Z; Guo, X; Huang, F; Li, Y; Liu, H; Liu, Q; Nie, D; Song, Z; Sun, J; Tu, S; Xiao, Y; Yu, G; Zhai, X; Zhang, Y; Zhou, H | 1 |
| Alexander, HD; Humphreys, MW; Kettle, PJ; McGrattan, P | 1 |
| Bargay, J; Brunet, S; Caballero, MD; Canals, C; Léon, A; Martino, R; Moraleda, JM; Pérez-Simón, JA; San Miguel, J; Sanz, GF; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Adams, DJ; Chao, NJ; DeCastro, CM; Foster, T; Gasparetto, C; Gockerman, JP; Ibom, VK; Long, GD; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL; Thompson, M; Vredenburgh, JJ | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Buquicchio, C; Carluccio, P; Greco, G; Liso, A; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G | 1 |
| Beyer, J; Biersack, H; Bornhäuser, M; Ehninger, G; Kiehl, M; Kröger, N; Sayer, HG; Schäfer-Eckardt, K; Schwerdtfeger, R; Wandt, H; Zander, AR | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE | 1 |
| Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
| Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A | 1 |
| Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ | 1 |
| Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B | 1 |
| Da, WM; Li, HH; Wang, QS; Wang, SH; Wu, XX; Zhao, Y; Zhu, HY | 1 |
| Berdel, WE; Berning, B; Beyer, J; Bornhauser, M; Buchner, T; Ehninger, G; Fauser, AA; Heinecke, A; Kienast, J; Kroger, M; Neubauer, A; Sauerland, MC; Scheffold, C; Silling, G; Stelljes, M | 1 |
| Claxton, DF; Ehmann, C; Rybka, W | 1 |
| Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J | 1 |
| Alpay, R; Disel, U; Paydas, S; Tuncer, I; Yavuz, S | 1 |
| Albertioni, F; Löfgren, C; Paul, C | 1 |
| Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K | 1 |
| Abe, Y; Choi, I; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Shibata, K; Tachikawa, Y | 1 |
| Asano, S; Iseki, T; Konuma, T; Nakaoka, T; Ooi, J; Takahashi, S; Takasugi, K; Tojo, A; Tomonari, A; Tsukada, N; Uchiyama, M | 1 |
| Au, WY; Chan, LC; Kwong, YL; Liang, R | 1 |
| Iwasaki, H; Kawai, Y; Kishi, S; Takemura, H; Ueda, T; Urasaki, Y; Yamamoto, S; Yamauchi, T; Yoshida, A | 1 |
| Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; de Meis, E; Donato, M; Ghosh, S; Giralt, S; Hosing, C; Kebriaei, P; Khouri, I; Oran, B; Popat, U; Qazilbash, M; Saliba, R | 1 |
| Bocchia, M; Bucalossi, A; Defina, M; Forconi, F; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
| Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Martinez-González, O; Morales-Toquero, A; Ruiz-Argüelles, GJ; Salazar-Riojas, R; Tarín-Arzaga, LC | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR | 1 |
| Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M | 1 |
| Artz, AS; Daugherty, C; Godley, L; Huo, D; Larson, R; Odenike, OM; Pollyea, DA; Rich, E; Smith, SM; Stock, W; van Besien, K; Zhang, Y; Zimmerman, T | 1 |
| Canales, MA; de Paz, R; Hernandez-Navarro, F; Martin-Salces, M | 1 |
| Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W | 1 |
| Alonzo, TA; Arceci, RJ; Arndt, C; Barnard, DR; Dinndorf, P; Dusenbery, K; Feig, S; Feusner, J; Gerbing, RB; Heerema, NA; Lange, BJ; Luna-Fineman, S; Seibel, N; Shannon, K; Smith, FO; Weiman, M | 1 |
| Díaz, MA; González-Vicent, M; Madero, L; Pérez, A; Ramirez, M; Sevilla, J | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B | 1 |
| Bernal, MT; Besalduch, J; Brunet, MS; Caballero, D; Carrera, D; Ferra, C; Martin, J; Martino, R; Moraleda, JM; Nieto, JB; Perez-Simón, JA; Piñana, JL; Ribera, JM; Sampol, A; Sierra, J; Valcárcel, D; Vazquez, L | 1 |
| Li, F; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y | 1 |
| Besser, M; Cargill, JS; Craig, JI; Crawley, C; Enoch, DA; Follows, G; Gudgin, E; Ludlam, HA; Marcus, RE; Min, SY; Sartori, P; Todd, T | 1 |
| Fujiwara, M; Hashimoto, S; Koike, T; Satoh, N; Takenouchi, S | 1 |
| Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A | 1 |
| Huisman, C; Lokhorst, HM; Meijer, E; Petersen, EJ; Verdonck, LF | 1 |
| Agura, ED; Bethge, WA; Blume, KG; Bruno, B; Chauncey, TR; Curtin, PT; Epner, E; Forman, SJ; Lange, T; Laport, GG; Maloney, DG; Maris, MB; Petersen, FB; Sandmaier, BM; Scott, BL; Storb, RF; Storer, BE; Stuart, MJ; Wade, JC; Wong, RM | 1 |
| Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L | 1 |
| Bernardeschi, P; Del Conte, A; Dentico, P; Fiorentini, G; Giannessi, PG; Giustarini, G; Montenora, I; Rossi, S; Turrisi, G | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Atra, AA; Baothman, A; Elimam, NA; Kassar, A; Khattab, TM; Zayed, A | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Bakay, B; Bleeker, LC; Kung, FH; Matsumoto, SS; Nyhan, WL; Yu, AL | 1 |
| Bloch, A; Minowada, J; Takeda, K | 1 |
| Balcerzak, SP; Coleman, MS; Gray, DP; Grever, MR; Siaw, MF | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P | 1 |
| Manfori, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Gandhi, V | 1 |
| McCulloch, EA; Rayappa, C | 1 |
| Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 2 |
| Archimbaud, E; Thomas, X | 1 |
| Gandhi, V; Loughlin, S; Plunkett, W; Zwelling, LA | 1 |
| Estey, E; Kuschel, B | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Goldstone, AH; Harvey, D; Johnson, S; Nokes, TJ | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Bouabdallah, R; Cohen-Valensi, R; Coso, D; Costello, R; Gastaut, JA; Nezri, M; Sainty, D | 1 |
| Hann, IM; McCarthy, AJ; Oakhill, A; Pitcher, LA | 1 |
| Ballerini, F; Beltrami, G; Canepa, L; Carrara, P; Cavaliere, M; Celesti, L; Clavio, M; Gatto, S; Gobbi, M; Lanza, L; Miglino, M; Pierri, I; Pietrasanta, D; Quintino, S; Varese, P | 1 |
| Byrne, JL; Dasgupta, E; Forman, K; Haynes, AP; Mitchell, D; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Higashi, Y; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Canepa, L; Carrara, S; Cerri, R; Clavio, M; Damasio, E; Gobbi, M; Masoudi, B; Miglino, M; Muner, P; Pierri, I; Quintino, S | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Estey, EH | 1 |
| Ehninger, G; Fiedler, F; Friedrichsen, K; Hänel, A; Hänel, M; Herbst, R; Morgner, A; Neser, S; Nicklisch, M; Teich, M | 1 |
| Du, EZ; Friedman, PJ; Le, DT; Masliah, E; Yi, ES; Yung, GL | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Bhalla, K; Grant, S; McCrady, C; Pettit, GR; Traylor, R | 1 |
| Kelleher, CA; McCulloch, EA; Minkin, S; Wang, YF | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Kufe, DW; Spriggs, DR | 1 |
14 review(s) available for vidarabine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2018 |
Fludarabine: a review of the clear benefits and potential harms.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Vidarabine | 2013 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?
Topics: Adult; Antilymphocyte Serum; Child; Comorbidity; Cyclophosphamide; Cyclosporine; Graft vs Leukemia Effect; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation.
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 13; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Vidarabine | 2002 |
Fludarabine for treatment of adult acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Hematopoietic Cell Growth Factors; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Vidarabine | 1995 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Therapeutic options for acute myelogenous leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Prognosis; Topotecan; Vidarabine | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
Biochemical and cellular pharmacology of cytosine arabinoside.
Topics: Animals; Aphidicolin; Arabinofuranosylcytosine Triphosphate; Binding, Competitive; Cell Line; Cell Survival; Centrifugation, Density Gradient; Cytarabine; Diterpenes; DNA; DNA Repair; DNA Replication; Fibroblasts; Granulocytes; Humans; Kinetics; Leukemia L1210; Leukemia, Myeloid, Acute; Nucleic Acid Synthesis Inhibitors; Templates, Genetic; Vidarabine | 1985 |
138 trial(s) available for vidarabine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Transplantation, Homologous; Vidarabine | 2021 |
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Remission Induction; Vidarabine | 2022 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine | 2022 |
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat | 2022 |
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Vidarabine; Vorinostat | 2022 |
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2022 |
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine | 2022 |
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Topics: Aged; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cell Membrane; Cytotoxicity, Immunologic; Female; Humans; Immunoglobulin Fc Fragments; Interleukin-2; Interleukins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Mice; Middle Aged; Protein Binding; Protein Engineering; Sialic Acid Binding Ig-like Lectin 3; Vidarabine | 2020 |
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine | 2020 |
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Retrospective Studies; Survival Rate; Vidarabine; Vincristine | 2021 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine | 2017 |
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Vidarabine | 2017 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
Topics: Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine | 2018 |
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Retrospective Studies; Risk Factors; Time Factors; Vidarabine | 2018 |
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine | 2019 |
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.
Topics: Adult; Allografts; Benzylamines; Busulfan; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proteomics; Signal Transduction; Transplantation Conditioning; Vidarabine | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
Topics: Aged; Bone Marrow; Female; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Lewis Blood Group Antigens; Male; Middle Aged; Receptors, Antigen, T-Cell; Remission Induction; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2013 |
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult | 2014 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome; Vidarabine; Young Adult | 2014 |
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Re-induction with L-DNR/FLAG improves response after AML relapse, but not long-term survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Female; Follow-Up Studies; Germany; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Polyethylene Glycols; Remission Induction; Retreatment; Selection Bias; Survival Rate; Vidarabine; Young Adult | 2014 |
Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.
Topics: Adolescent; Adult; Aged; Allografts; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2016 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2015 |
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Drug Administration Schedule; Female; Gemtuzumab; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy; Immunotoxins; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Sialic Acid Binding Ig-like Lectin 3; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine; Young Adult | 2016 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Prospective Studies; Proto-Oncogene Proteins c-kit; Translocation, Genetic; Vidarabine; Young Adult | 2017 |
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Salvage Therapy; Tissue Distribution; Vidarabine | 2008 |
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Vidarabine | 2008 |
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukemia, Myeloid, Acute; Lymphocytes; Male; Melphalan; Middle Aged; Neoplastic Cells, Circulating; Transplantation Conditioning; Transplantation, Homologous; Tumor Burden; Vidarabine | 2009 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine | 2009 |
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 2009 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
[Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine; Young Adult | 2009 |
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Disease-Free Survival; Genes, Immunoglobulin Heavy Chain; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; London; Mutation; Proportional Hazards Models; Risk Assessment; Risk Factors; Rituximab; Survival Rate; Time Factors; Treatment Outcome; United States; Vidarabine | 2011 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Medical Records; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Topics: Antigens, CD; Cell Separation; Cyclophosphamide; Flow Cytometry; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Immunotherapy, Adoptive; Interleukin-2; Killer Cells, Natural; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, KIR; Recurrence; Remission Induction; Risk Factors; Transplantation, Homologous; Vidarabine | 2011 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Models, Statistical; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
[The clinical comparison of FLAG regimen versus IA regimen for newly diagnosed acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytarabine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indicators and Reagents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Vidarabine | 2012 |
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine | 2013 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Odds Ratio; Remission Induction; Research Design; Treatment Outcome; Vidarabine | 2013 |
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Esophagitis; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Metabolic Clearance Rate; Middle Aged; Recurrence; Stomatitis; Vidarabine | 2003 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine | 2003 |
[Modified FLAG regimen in the management of refractory acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2003 |
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine | 2004 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine | 2004 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine | 2005 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Topics: Adult; Aged; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sepsis; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survivors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mexico; Middle Aged; Recurrence; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2008 |
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Idarubicin; Infant; Infant, Newborn; Interleukin-2; Leukemia, Myeloid, Acute; Male; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine | 2008 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine | 2008 |
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Topics: Adult; Age Factors; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Conjunctivitis; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1993 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1998 |
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Blast Crisis; Cell Cycle; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Pilot Projects; Vidarabine | 1995 |
FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 1999 |
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Vidarabine | 1999 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Rate; Vidarabine | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
269 other study(ies) available for vidarabine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2022 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine | 2022 |
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2022 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Topics: Antigens, CD19; Child; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2022 |
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Topics: Alkylating Agents; AMP-Activated Protein Kinases; Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Caspase 3; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Nucleosides; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; STAT5 Transcription Factor; Sulfonamides; Transplantation Conditioning; Vidarabine | 2022 |
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Vidarabine | 2022 |
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Single-dose (4.5 mg/m
Topics: Adult; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Vidarabine | 2022 |
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Vidarabine; Young Adult | 2022 |
Transplantation provides superior survival high risk myeloid malignancies in older patients.
Topics: Aged; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasms; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2023 |
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Vidarabine | 2023 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2023 |
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridge Therapy; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2023 |
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
Topics: Adult; Anthracyclines; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Vidarabine | 2023 |
Busulfan and subsequent malignancy: An evidence-based risk assessment.
Topics: Adult; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Risk Assessment; Transplantation Conditioning; Vidarabine | 2024 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Proportional Hazards Models; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine | 2020 |
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2020 |
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine | 2021 |
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Topics: Age Factors; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2020 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Rate; Vidarabine | 2020 |
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine | 2021 |
Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
Topics: Busulfan; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Topics: Age Factors; Aged; Busulfan; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Radiation Dosage; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2020 |
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acut
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2021 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2021 |
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2020 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2021 |
Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Humans; Leukemia, Myeloid, Acute; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2021 |
Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Retrospective Studies; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2021 |
Syngeneic leukemia models using lentiviral transgenics.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Viral; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Immunocompetence; Lentivirus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Oncogenes; Transplantation, Isogeneic; Vidarabine | 2021 |
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pancytopenia; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2021 |
Conditioning with 10 Gy Total Body Irradiation, Cyclophosphamide, and Fludarabine without ATG Is Associated with Improved Outcome of Cord Blood Transplantation in Children with Acute Leukemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2021 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Vidarabine | 2021 |
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes | 2017 |
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Melphalan; Middle Aged; Myelodysplastic Syndromes; Rabbits; Risk Assessment; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Patient Selection; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2018 |
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Vascularized Composite Allotransplantation; Vidarabine | 2017 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2017 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2018 |
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Staging; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Case-Control Studies; Chemical and Drug Induced Liver Injury; Clofarabine; Cohort Studies; Combined Modality Therapy; Cost Savings; Costs and Cost Analysis; Cytarabine; Granulocyte Colony-Stimulating Factor; Hospital Costs; Humans; Incidence; Induction Chemotherapy; Length of Stay; Leukemia, Myeloid, Acute; Michigan; Middle Aged; Neutropenia; Propensity Score; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Vidarabine | 2018 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine | 2018 |
High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction; Salvage Therapy; Survival Analysis; United Kingdom; Vidarabine | 2018 |
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Down Syndrome; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Vidarabine; Vorinostat | 2019 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Busulfan; China; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2018 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla
Topics: Busulfan; Europe; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.
Topics: Adolescent; Adult; Busulfan; China; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Vidarabine; Young Adult | 2019 |
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
Topics: Aged; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Topics: Adult; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Transplantation Conditioning; Vidarabine | 2018 |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine | 2018 |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult | 2018 |
Chemotherapy based combinations in AML: Time to take a step back?
Topics: Anthracyclines; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2018 |
Sequential reduced-intensity chemotherapy for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia with rare cytogenetic abnormalities transformed from Fanconi anemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Fanconi Anemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Red-Cell Aplasia, Pure; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Purines; Remission Induction; RNA, Long Noncoding; Vidarabine | 2018 |
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vidarabine | 2019 |
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine | 2019 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2013 |
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine | 2013 |
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2013 |
Fludarabine in Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Disease-Free Survival; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2014 |
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Salvage Therapy; Vidarabine | 2014 |
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Secondary Prevention; Survival Analysis; Vidarabine | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
Topics: Adolescent; Antineoplastic Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Immunosuppression Therapy; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; T-Lymphocytes; Vidarabine; Virus Activation; Young Adult | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Vidarabine | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
[Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Female; Graft Survival; Graft vs Host Disease; Haplotypes; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Vidarabine | 2015 |
[Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
Topics: Adolescent; Adult; Allografts; Cytarabine; Disease-Free Survival; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Vidarabine; Young Adult | 2014 |
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2015 |
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine | 2015 |
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine | 2015 |
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Topics: Adult; Aged; Busulfan; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2015 |
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.
Topics: Adult; Aged; Benzylamines; Busulfan; Cell Movement; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cohort Studies; Cross-Sectional Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; B-Lymphocyte Subsets; Blood Component Removal; Busulfan; Cross-Sectional Studies; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Factors; T-Lymphocyte Subsets; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Turkey; Vidarabine | 2015 |
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine | 2015 |
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.
Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Busulfan-based conditioning regimens: not all partners are equal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Transplantation Conditioning; Vidarabine | 2015 |
Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Female; Granulocyte Colony-Stimulating Factor; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Malate Dehydrogenase; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Salvage Therapy; Translocation, Genetic; Vidarabine | 2015 |
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion?: Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysi
Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Transplantation Conditioning; Vidarabine | 2016 |
Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia--Authors' reply.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Transplantation Conditioning; Vidarabine | 2016 |
Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Transplantation Conditioning; Vidarabine | 2016 |
Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Topics: Adolescent; Adult; Anthracyclines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; China; Consolidation Chemotherapy; Cytarabine; Female; Humans; Incidence; Infant; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prospective Studies; Survival Rate; Vidarabine; Young Adult | 2016 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbidity; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
[Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Wernicke's Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Thiamine; Vidarabine; Wernicke Encephalopathy | 2016 |
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2016 |
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Vidarabine; Young Adult | 2016 |
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Cytarabine; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Stem Cell Transplantation; Survival Rate; Vidarabine | 2017 |
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Leukocyte Reduction Procedures; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine | 2017 |
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Core Binding Factors; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Mitoxantrone; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
Topics: Adult; Antineoplastic Agents; Bacteremia; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine | 2008 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 2008 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Rabbits; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Aged; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2009 |
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Molecular identification of phaeohyphomycosis due to Alternaria infectoria in a patient with acute myeloid leukemia--a case report.
Topics: Adolescent; Alternaria; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Mycoses; Nasal Cavity; Polymerase Chain Reaction; Rhinitis; Vidarabine | 2010 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Topics: Adolescent; Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Feasibility Studies; Female; Haplotypes; Humans; Immunotherapy; Infant; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Topics: Adolescent; Antigens, CD19; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2010 |
Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Confidence Intervals; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2010 |
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Treatment Outcome; Vidarabine | 2011 |
FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Thailand; Vidarabine; Young Adult | 2010 |
Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Assessment; Vidarabine | 2010 |
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
Topics: Area Under Curve; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine | 2011 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2010 |
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Salvage Therapy; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Topics: Adult; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Reoperation; Republic of Korea; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vidarabine | 2010 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
Topics: Adult; Aged; Area Under Curve; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2011 |
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Cyclosporine; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mycophenolic Acid; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
[FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Prognosis; Recurrence; Remission Induction; Tandem Repeat Sequences; Vidarabine | 2011 |
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Translocation, Genetic; Vidarabine | 2011 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Retrospective Studies; Translocation, Genetic; Vidarabine | 2012 |
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Rabbits; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine | 2012 |
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine | 2013 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cyclophosphamide; DNA Probes; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Rituximab; Translocation, Genetic; Vidarabine | 2012 |
[Effects of IAT and MAT chemotherapeutic regimens in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2012 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Vidarabine | 2013 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine | 2005 |
[Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Respiratory Tract Infections; Treatment Outcome; Vidarabine | 2005 |
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease Progression; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Sirolimus; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Methylprednisolone; Neutropenia; Recombinant Proteins; Recurrence; Sweet Syndrome; Vidarabine | 2006 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
[Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].
Topics: Antineoplastic Agents; Cyclophosphamide; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2007 |
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine | 2007 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Middle Aged; Rituximab; Vidarabine | 2008 |
Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.
Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft vs Leukemia Effect; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Prospective Studies; Recurrence; Stem Cells; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
[Effects of FLAG protocol in treatment of the first time induced non-remission acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Vidarabine; Young Adult | 2007 |
Invasive fungal sinusitis in patients treated with fludarabine.
Topics: Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus flavus; Aspergillus fumigatus; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucormycosis; Rhizopus; Sinusitis; Vidarabine | 2008 |
Switching of donor cells after urgent second cord blood transplantation for suspected graft failure.
Topics: Adult; Anti-Inflammatory Agents; Bone Marrow; Cord Blood Stem Cell Transplantation; Delayed Graft Function; Donor Selection; Female; Ferritins; Graft Survival; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Macrophages; Methylprednisolone; Myeloablative Agonists; Tissue Donors; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2007 |
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2008 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Saudi Arabia; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Topics: Adenosine Deaminase; Adolescent; Deoxyadenine Nucleotides; Deoxyadenosines; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Lymphoma; Male; Nucleotidases; Pentostatin; Thymidine; Vidarabine | 1982 |
Kinetics of appearance of differentiation-associated characteristics in ML-1, a line of human myeloblastic leukemia cells, after treatment with 12-O-tetradecanoylphorbol-13-acetate, dimethyl sulfoxide or 1-beta-D-arabinofuranosylcytosine.
Topics: Cell Cycle; Cell Differentiation; Cell Line; Cell Survival; Dimethyl Sulfoxide; Humans; Kinetics; Leukemia, Myeloid, Acute; Phorbols; Tetradecanoylphorbol Acetate; Vidarabine | 1982 |
2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
Topics: Adenosine Deaminase; Adult; Coformycin; Deoxyribonucleotides; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Nucleosides; Pentostatin; Ribonucleosides; Ribonucleotides; Vidarabine | 1982 |
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Vidarabine | 1994 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Methylcellulose; Vidarabine | 1993 |
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 1993 |
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Topics: Antineoplastic Agents; Cell Cycle; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Binding; Tumor Cells, Cultured; Vidarabine | 1996 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Vidarabine | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Vidarabine | 1999 |
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 1999 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine | 2000 |
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cytarabine; Drug Costs; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Alveolar Proteinosis; Tomography, X-Ray Computed; Vidarabine | 2001 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Clone Cells; Drug Interactions; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lactones; Leukemia, Myeloid, Acute; Macrolides; Middle Aged; Recombinant Proteins; Vidarabine | 1992 |
Effects of rGM-CSF and rG-CSF on the cisplatin sensitivity of the blast cells of acute myeloblastic leukemia.
Topics: Cell Cycle; Cell Division; Cell Survival; Cisplatin; DNA, Neoplasm; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Methylcellulose; Recombinant Proteins; Thymidine; Tritium; Tumor Cells, Cultured; Vidarabine | 1991 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |